Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs.

"data availability data will be made available on request. acknowledgements funding: the research was supported by the grants ro1 ai131424"

"Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper"

"Funding: The research was supported by the 10.13039/100000060National Institute of Allergy and Infectious Diseases, National Institutes of Health grants RO1 AI131424 (RTS) and 1RO1 AI161348 (RTS, KYH, AFC), the 10.13039/100000865Bill & Melinda Gates Foundation, the San Diego Center for AIDS Research (KYH, RTS, AFC), CDC core funding (MKL, JMM, and CFS), as well as NIH grant K08 AI130381 and Career Award for Medical Scientists from the Burroughs Welcome Fund (AFC). REM and JEF were partially supported by an institutional award to the UCSD Genetics Training Program from the National Institute for General Medical Sciences, T32 GM145427. The findings and conclusions in this report are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention."